BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26932687)

  • 1. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
    Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
    Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
    Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR;
    Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
    Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
    Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
    Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
    Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
    Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
    Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
    Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
    Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
    Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
    Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
    Murata S; Takeuchi Y; Yamanaka K; Hayakawa J; Yoshida M; Yokokawa R; Wakana A; Sawata M; Tanaka Y
    Jpn J Infect Dis; 2019 Sep; 72(5):299-305. PubMed ID: 31155600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.